Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 6
2005 8
2006 6
2007 6
2008 5
2009 4
2010 10
2012 6
2013 7
2014 5
2015 8
2016 3
2017 6
2018 1
2019 3
2020 3
2021 6
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Immune evasion by Kaposi's sarcoma-associated herpesvirus.
Lee HR, Lee S, Chaudhary PM, Gill P, Jung JU. Lee HR, et al. Among authors: gill p. Future Microbiol. 2010 Sep;5(9):1349-65. doi: 10.2217/fmb.10.105. Future Microbiol. 2010. PMID: 20860481 Free PMC article. Review.
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C. Randolph ME, et al. Among authors: gill p. PLoS One. 2017 Aug 17;12(8):e0183161. doi: 10.1371/journal.pone.0183161. eCollection 2017. PLoS One. 2017. PMID: 28817624 Free PMC article.
The origin of Kaposi sarcoma.
Gill PS. Gill PS. J Natl Cancer Inst. 2007 Jul 18;99(14):1063. doi: 10.1093/jnci/djm063. Epub 2007 Jul 10. J Natl Cancer Inst. 2007. PMID: 17623793 No abstract available.
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. Sadeghi S, et al. Among authors: gill ps. J Clin Oncol. 2023 Jan 20;41(3):640-650. doi: 10.1200/JCO.21.02923. Epub 2022 Aug 19. J Clin Oncol. 2023. PMID: 35984996 Clinical Trial.
Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS. Tafuri A, et al. Among authors: gill ps. Clin Genitourin Cancer. 2020 Oct;18(5):351-360.e3. doi: 10.1016/j.clgc.2020.01.004. Epub 2020 Jan 31. Clin Genitourin Cancer. 2020. PMID: 32146152 Free PMC article. Review.
AXL mediates resistance to cetuximab therapy.
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. Brand TM, et al. Among authors: gill ps. Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18. Cancer Res. 2014. PMID: 25136066 Free PMC article.
Identifying aggressive prostate cancer foci using a DNA methylation classifier.
Mundbjerg K, Chopra S, Alemozaffar M, Duymich C, Lakshminarasimhan R, Nichols PW, Aron M, Siegmund KD, Ukimura O, Aron M, Stern M, Gill P, Carpten JD, Ørntoft TF, Sørensen KD, Weisenberger DJ, Jones PA, Duddalwar V, Gill I, Liang G. Mundbjerg K, et al. Among authors: gill p. Genome Biol. 2017 Jan 12;18(1):3. doi: 10.1186/s13059-016-1129-3. Genome Biol. 2017. PMID: 28081708 Free PMC article.
94 results